DocWire News Editors

DocwireNews

A team of researchers from the University of York have recently developed a test that can distinguish manageable from fatal prostate cancers with up to 92% accuracy. &nbsp;This breakthrough could potentially reduce the number of unnecessary surgeries and radiotherapy sessions. The study was published in the British Journal of Cancer, and funder by The Freemasons of the Province of Yorkshire and the Masonic Samaritan Fund.Identifying genetic biomarkers that are altered in different cancer types, the team was able to show in their study that over 25 men are unnecessarily treated with radiotherapy or surgery for every one life that is saved. Success rates could potentially be lessened as a result of unnecessarily treating prostate cancers all in the same manner.Professor Norman Maitland, from the Department of Biology at University of York&rsquo;s said, &ldquo;Unnecessary prostate treatment has both physical consequences for patients and their families but is also a substantial financial burden on the NHS, where each operation will cost around &pound;10,000. Cancers that are contained in the prostate, however, have the potential to be &lsquo;actively monitored&rsquo; which is not only cheaper, but has far fewer negative side-effects in patients with non-life threatening cancer.&rdquo;To identify varying magnitudes of cancer, scientists must analyze genes that research has linked to aggressive cancers. In their study, the researchers analyzed over 500 cancer tissue samples and compared with non-cancerous tissues to detect patterns of a chemical group added to the genetic material to alter gene expression.Factors affecting this gene expression include age, diet, and sleep, all of which impacting chemical alterations that can turn genes on and off. This process is integral to the normally functioning body, however when it malfunctions it can cause several diseases.Using a computer algorithm, the scientists were able to cancel out noise caused by genetic patterns unique to the individual and identify specific patterns indicative of cancer. What they were left with was 17 possible biomarkers for prostate cancer.&ldquo;In some diseases, such as cancer, genes can be switched to an opposite state, causing major health issues and threat to life,&rdquo; said Professor Maitland. &ldquo;The challenge in prostate cancer is how to look at all of these patterns within a cell, but hone in on the gene activity that suggests cancer, and not only this, what type of cancer &ndash; dangerous or manageable? To put it another way: how to do we distinguish the tiger cancer cells from the pussycat cancer cells, when there are millions of patterns of chemical alterations going on, many of which will be perfectly healthy?&rdquo;Looking to integrate this technique into the clinical setting, the team is looking into developing a trial with new cancer samples, and to involve a partner to allow the test to be used on patients being treated in the NHS.Dr Davide Pellacani, a researcher who began these studies in York before relocating to the University of British Columbia, said, &ldquo;Using this computer analysis, not only could we see which tissue samples had cancer and which didn&rsquo;t, but also which cancers were dangerous and which ones less so. Out of almost a million markers studied, we were able to use our new tools to single out differences in cancer potency.&rdquo;<blockquote class="twitter-tweet" data-lang="en">
Methylation Markers Distinguish Aggressive from Manageable Prostate Cancer: Scientists in the U.K. and Canada have identified a DNA methylation signature that they claim can distinguish aggressive prostate cancer from more manageable disease with up to&hellip; <a href="https://t.co/y3aUBIW4Z5">https://t.co/y3aUBIW4Z5</a>
&mdash; Epigenetics News (@Epigenetics) <a href="https://twitter.com/Epigenetics/status/1052920720144052225?ref_src=twsrc%5Etfw">October 18, 2018</a>
</blockquote><script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script>Sources: <a href="https://www.eurekalert.org/pub_releases/2018-10/uoy-dfp101718.php">EurekAlert</a>, <a href="https://www.nature.com/articles/s41416-018-0236-1">British Journal of Cancer</a>

Jayme Locke, MD, MPH

Joel M. Topf, MD, FACP

The Promise of Xenotransplantation

NKF Spring Clinical Meetings 2025

Leah Lawrence

Real-World Data Backs Invasive DFS as Surrogate Endpoint for OS in EBC

HR Breast Cancer

Sacituzimab Govitecan Showed Modest Activity for CNS Metastases

Triple-Negative Breast Cancer

Latest News

York Researchers Develop Test to Tell Manageable Prostate Cancer From Fatal

Future of Medicine

A team of researchers from the University of York have recently developed a test that can distinguish manageable from fatal prostate cancers with up to 92% accuracy.  This ...

About Us

Editorial Policy

Advertising

Contact Us

eNewsletters

Contribute

Career Center

MashupMD

Blood Cancers Today

Cancer Nursing Today

GU Oncology Now

Urban Health Today

Bile Duct Cancer

Colorectal Cancer

Gastroesophageal Cancer

Gastric Cancer

GEP-NETs

GIST

Liver Cancer

Pancreatic Cancer

GI Oncology Now

Anemia

Deep Vein Thrombosis

Essential Thrombocythemia

Hemophilia

Immune Thrombocytopenic Purpura

Myelodysplastic Syndromes

Myelofibrosis

Myeloproliferative Neoplasms

Polycythemia Vera

Pulmonary Embolism

Sickle Cell Disease

Thrombocytopenia

Thrombophilia

Thrombosis

Thrombotic Thrombocytopenic Purpura

Venous Thromboembolism

von Willebrand Disease

Heme Today

Acute Kidney Injury

ADPKD

Anemia and Kidney Disease

Chronic Kidney Disease

COVID-19 and Kidney Disease

Diabetes and Hypertension

End-Stage Renal Disease

Gout

Hyperkalemia

IgAN

Kidney Transplantation

Metabolic Acidosis

Nephrology Times

HER2 Breast Cancer

Genetics & Breast Cancer

Breast Cancers Today

Atherosclerotic Disease

Atrial Fibrillation

Heart Failure

Hypertension

Interventional Cardiology

Lipid Management

Practice Tips With Dr. Lichaa

Preventive Cardiology

Stroke

Cardiology

Breast Cancer

Gynecologic Cancer

Head and Neck Cancer

Skin Cancer

Oncology

Sleep

Urology

Diabetes

Ophthalmology

— Demodex Blepharitis

Neurology

Rheumatology

Gastroenterology

Pulmonology

Infectious Diseases

— HIV

Health and Wellness

Lupus

Orthopedics

Pharmacology

Career News

More

Conferences

CardioNerds

The Sleep Source With Dr. Morse

Rheumatology Rounds With Dr. Maheswaranathan

Partners

Expert Interviews

Subscribe